secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277504
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx expands Kite partnership: $85M upfront, $200M equity at $61.68/sh; cash runway to 2027
--------------------------------------------------------------------------------

- Kite exercises option for ARC-SparX program ACLX-001 in multiple myeloma; collaboration expanded to lymphomas for CART-ddBCMA.
- Arcellx receives $85M upfront cash; Gilead purchases 3,242,542 shares at $61.68/sh for $200M; Gilead ownership ~13%.
- Cash runway extended into 2027; transaction expected close year-end 2023, subject to HSR clearance.
- Potential milestone payments to offset prespecified development costs; operational efficiencies identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/0001193125-23-277504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/d850591d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer